bi-4scar cd19/79b t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2022 (NCT05436509)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-cell antigen receptor complex-associated protein beta chainImmunity, passive
CD79B immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05436509 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2022 | Shenzhen Geno-Immune Medical Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1